Atrium Therapeutics, Inc. (RNA) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Diego, CA, United States. वर्तमान CEO हैं Kathleen Gallagher.
RNA के पास है IPO तिथि 2026-02-27, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $217.52M.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
